Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer

Nuclear Medicine Communications

Volumn 34, Issue 12, 2013, Pages 1157-1165

  Beylergil, Volkan ^a   Morris, Patrick G ^b   Smith Jones, Peter M ^a,g   Modi, Shanu ^b,f   Solit, David ^c   Hudis, Clifford A ^b,f   Lu, Yang ^a,i   O'Donoghue, Joseph ^d   Lyashchenko, Serge K ^e   Carrasquillo, Jorge A ^a,d   Larson, Steven M ^a,d   Akhurst, Timothy J ^a,d,h  

^a Molecular Imaging and Therapy Service   (United States)

^b Solid Tumor Division   (United States)

^c Human Oncology and Pathogenesis Program   (United States)

^d Department of Medical Physics ^*  (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

ⁱ UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

Author keywords

68Ga; breast cancer; F(ab0)2 trastuzumab; Herceptin; PET CT

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID GA 68 F(AB')2 TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RADIOPHARMACEUTICAL AGENT; TRASTUZUMAB; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; DIAGNOSTIC AGENT; GALLIUM; MONOCLONAL ANTIBODY; SINGLE HETEROCYCLIC RINGS; TETRAXETAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; DRUG DISTRIBUTION; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; PERSONAL EXPERIENCE; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; BREAST TUMOR; CHEMISTRY; METASTASIS; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; RADIOGRAPHY; RADIOMETRY; SAFETY; SCINTISCANNING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; FEASIBILITY STUDIES; FEMALE; GALLIUM RADIOISOTOPES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM METASTASIS; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; SAFETY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84887255974     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328365d99b     Document Type: Article

References (34)

1. Slamon DJ, Clark GM,Wong SG, Levin WJ, Ullrich A, Mcguire WL. Humanbreast cancer-correlation of relapse and survival with amplification of the HER-2 neu oncogene. Science 1987; 235:177-182.
2. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39-51.
3. Arteaga CL, Baselga J. Impact of genomics on personalized cancer medicine. Clin Cancer Res 2012; 18:612-618.
4. Yin W, Jiang Y, Shen Z, Shao Z, Lu J. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients:a meta-analysis of published randomized controlled trials. Plos One 2011; 6:e21030.
5. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing:biologic and methodologic considerations. J Clin Oncol 2009; 27:1323-1333.
6. Behr TM, Behe M, Wormann B. Trastuzumab and breast cancer. N Engl J Med 2001; 345:995-996.
7. Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006; 24:2276-2282.
8. Niu G, Li Z, Cao Q, Chen X. Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu- DOTAtrastuzumab. Eur J Nucl Med Mol Imaging 2009; 36:1510-1519.
9. Moreau M, Raguin O, Vrigneaud JM, Collin B, Bernhard C, Tizon X, et al. DOTAGA-trastuzumab. A new antibody conjugate targeting HER2/neu antigen for diagnostic purposes. Bioconjug Chem 2012; 9:1181-1188.
10. Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 2009; 50:974-981.
11. Gaykema SB, Brouwers AH, Hovenga S, Lub-de Hooge MN, de Vries EG, Schroder CP. Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer. J Clin Oncol 2012; 30:e74-e75.
12. Holland JP, Caldas-Lopes E, Divilov V, Longo VA, Taldone T, Zatorska D, et al. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. Plos One 2010; 5:e8859.
13. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004; 22:701-706.
14. Smith-Jones PM, Solit DB. Generation of DOTA-conjugated antibody fragments for radioimmunoimaging. Methods Enzymol 2004; 386:262-275.
15. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal-antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984; 72:77-89.
16. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
17. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
18. Dawood S, Giordano SH. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease-reply to G. Ferretti et al. J Clin Oncol 2010; 28:E338-E339.
19. Cobleigh M. Herceptin (R) is active as a single agent in women with metastatic breast cancer overexpressing HER2. Eur J Cancer 1999; 35:S316.
20. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-2648.
21. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-726.
22. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET:comparison with F-18-FDG PET. J Nucl Med 2006; 47:793-796.
23. Munnink THO, de Korte MA, Nagengast WB, Timmer-Bosscha H, Schroder CP, de Jong JR, et al. Zr-89-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur J Cancer 2010; 46:678-684.
24. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010; 87:586-592.
25. Spiridon CI, Guinn S, Vitetta ES. A comparison of the in vitro and in vivo activities of IgG and F(ab0)2 fragments of a mixture of three monoclonal anti-Her-2 antibodies. Clin Cancer Res 2004; 10:3542-3551.
26. Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 2005; 65:5907-5916.
27. Ren G,Webster JM, Liu Z, Zhang R, Miao Z, Liu H, et al. In vivo targeting of HER2-positive tumor using 2-helix affibody molecules. Amino acids 2012; 43:405-413.
28. Baum RP, Prasad V, Muller D, Schuchardt C, Orlova A, Wennborg A, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules. J Nucl Med 2010; 51:892-897.
29. Kramer-Marek G, Shenoy N, Seidel J, Griffiths GL, Choyke P, Capala J. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur J Nucl Med Mol Imaging 2011; 38:1967-1976.
30. Tolmachev V, Velikyan I, Sandstrom M, Orlova A. A. HER2-binding affibody molecule labelled with 68Ga for PET imaging:direct in vivo comparison with the 111In-labelled analogue. Eur J Nucl Med Mol Imaging 2010; 37:1356-1367.
31. Massuger L, Claessens R, Kenemans P, Verheijen RHM, Boerman OC, Meeuwis APW, et al. Kinetics and biodistribution in relation to tumordetection with In-111 labeled OV-TL 3 F(ab0)2 in patients with ovariancancer. Nucl Med Commun 1991; 12:593-609.
32. Kalofonos HP, Sivolapenko GB, Courtenayluck NS, Snook DE, Hooker GR, Winter R, et al. Antibody guided targeting of non-small cell lung-cancer using In-111-labeled HMFG1 F(ab0)2 fragments. Cancer Res 1988; 48:1977-1984.
33. Brouwers A, Mulders P, Oosterwijk E, Buijs W, Corstens F, Boerman O, et al. Pharmacokinetics and tumor targeting of I-131-labeled F(ab0)(2) fragments of the chimeric monoclonal antibody G250:preclinical and clinical pilot studies. Cancer Biother Radiopharm 2004; 19:466-477.
34. De Bree R, Roos JC, Quak JJ, den Hollander W,Wilhelm AJ, van Lingen A, et al. Biodistribution of radiolabeled monoclonal antibody E48 IgG and F(ab0)2 in patients with head and neck cancer. Clin Cancer Res 1995; 1:277-286.